Ann Thorac Surg 2008;86:910-911. doi:10.1016/j.athoracsur.2008.07.008
© 2008 The Society of Thoracic Surgeons
Original Articles: General Thoracic
Invited Commentary
Ken Kodama, MD
Department of Thoracic Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3, Nakamichi, Higashinari-ku, Osaka, 537-8511 Japan
(Email: kodama-ke@mc.pref.osaka.jp).
| The first 20% of the full text of this article appears below. |
Although several trials of induction chemoradiotherapy followed by surgery have been reported to date, the role of tri-modality therapy in stage III nonsmall cell lung cancer (NSCLC) is highly controversial. Edelman and colleagues [1] reported the results of a phase I–II trial of maximally local and systemic disease control for biopsy proven stage IIIA or IIIB NSCLC. The main objective was to determine the ability to intensify tri-modality therapy using concurrent 69.6 Gy of hyperfractionated radiotherapy and more aggressive consolidative chemotherapy. As . . . [Full Text of this Article]
Related Article
-
Phase I/II Trial of Hyperfractionated Radiation and Chemotherapy Followed by Surgery in Stage III Lung Cancer
- Martin J. Edelman, Mohan Suntharalingam, Whitney Burrows, King F. Kwong, Neha Mitra, Ziv Gamliel, Michelle Riley, Lindsay B. Cooper, Nancy L. Kennedy, Susan Buskirk, Petr Hausner, L. Austin Doyle, and Mark J. Krasna
Ann. Thorac. Surg. 2008 86: 903-910.
[Abstract]
[Full Text]
[PDF]
Copyright © 2008 by The Society of Thoracic Surgeons.